DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,720,852 | +13.3% | 293,111 | +9.6% | 1.07% | +13.9% |
| Q2 2023 | $64,203,635 | +0.7% | 267,515 | +5.8% | 0.94% | -3.2% |
| Q1 2023 | $63,735,875 | +96670.4% | 252,880 | +1.9% | 0.97% | -6.3% |
| Q4 2022 | $65,863 | -99.9% | 248,148 | +6.4% | 1.03% | +1.7% |
| Q3 2022 | $60,260,000 | +1.2% | 233,304 | -0.7% | 1.02% | +9.4% |
| Q2 2022 | $59,549,000 | -15.7% | 234,890 | -2.5% | 0.93% | -8.1% |
| Q1 2022 | $70,671,000 | -10.9% | 240,927 | -0.0% | 1.01% | -2.8% |
| Q4 2021 | $79,281,000 | +0.6% | 240,968 | -6.9% | 1.04% | -4.1% |
| Q3 2021 | $78,777,000 | +13.4% | 258,760 | -0.1% | 1.08% | +15.7% |
| Q2 2021 | $69,481,000 | +22.2% | 258,908 | +2.5% | 0.94% | +18.2% |
| Q1 2021 | $56,868,000 | +1.4% | 252,657 | +0.1% | 0.79% | -3.8% |
| Q4 2020 | $56,078,000 | +3.1% | 252,446 | -0.0% | 0.82% | -9.4% |
| Q3 2020 | $54,382,000 | -20.5% | 252,553 | -34.7% | 0.91% | -24.2% |
| Q2 2020 | $68,389,000 | +29.3% | 386,749 | +1.2% | 1.20% | +10.4% |
| Q1 2020 | $52,897,000 | -10.4% | 382,176 | -0.6% | 1.09% | +20.0% |
| Q4 2019 | $59,030,000 | – | 384,612 | – | 0.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |